v3.25.1
Revenue - Schedule of Product Sales (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue Recognition    
Total revenue $ 666,655 $ 93,855
Product sales    
Revenue Recognition    
Total revenue 621,678 89,836
Nuvaxovid sales    
Revenue Recognition    
Total revenue 608,025 82,324
Supply sales    
Revenue Recognition    
Total revenue $ 13,653 $ 7,512